Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio para evaluar la seguridad y eficacia de Tenapanor para el tratamiento del SII-E

18 de septiembre de 2026 actualizado por: Ardelyx

Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración para evaluar la seguridad y la eficacia de tenapanor para el tratamiento del síndrome del intestino irritable con estreñimiento (IBS-C) en pacientes pediátricos de 12 a menos de 18 años

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.

Descripción general del estudio

Descripción detallada

This study consists of 2-week screening period followed by 12 week randomized treatment period (RTP) and a 2-week treatment-free Follow-Up period (only for patients who will not enter the 40-week Long Term Safety Extension Study [TEN-01-306]). At the beginning of the 2-week Screening period, patients who provide written assent will be fully assessed for eligibility into the study and will be asked to self-report daily information about the status of their IBS symptoms via an electronic diary (eDiary) device. Patient compliance with the eDiary will be monitored actively by the site staff and will be reviewed to determine eligibility at the end of screening. Eligible patients will be randomized to receive one of the study medications: tenapanor 25 mg BID, tenapanor 50 mg BID, or placebo.

During the 12-week double-blind RTP, patients will continue recording daily assessments via the eDiary system as instructed and compliance with eDiary entries will be monitored on an ongoing basis. Patients will return for study visit every two or four weeks (Visits 3-6) and will undergo safety assessments at these visits.

Patients who do not enter the 40-week Long Term Safety Extension Study [TEN-01-306] including those who complete the RTP but do not enter study TEN-01-306 and those who prematurely discontinue from the RTP, a Follow-Up Visit will be scheduled approximately 2 weeks after the completion of the RTP (Visit 6) or the Early Termination Visit at which safety assessments will be performed

Tipo de estudio

Intervencionista

Inscripción (Actual)

180

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Foley, Alabama, Estados Unidos, 36535
        • G & L Research, LLC
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85745
        • Eclipse Clinical Research
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Applied Research Center of Arkansas
    • California
      • Anaheim, California, Estados Unidos, 92805
        • Advanced Research Center, Inc.
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06106
        • Connecticut Children's Medical Center
    • Florida
      • Doral, Florida, Estados Unidos, 33166
        • Prohealth Research Center
      • Kissimmee, Florida, Estados Unidos, 34741
        • I.H.S. Health, LLC
      • Miami, Florida, Estados Unidos, 33165
        • Valencia Medical and Research Center
      • Miami, Florida, Estados Unidos, 33155
        • Waterway Research & Associates Corp
      • Orlando, Florida, Estados Unidos, 32806
        • Orlando Health, Inc.- APH Center for Digestive Health and Nutrition
      • South Miami, Florida, Estados Unidos, 33143
        • Florida Pharmaceutical Research and Associates, Inc.
    • Georgia
      • Stockbridge, Georgia, Estados Unidos, 30281
        • Clinical Research Institute
    • Illinois
      • Peoria, Illinois, Estados Unidos, 61637
        • OSF Saint Francis Medical Center
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Riley Children's Health IUH
    • Maine
      • Portland, Maine, Estados Unidos, 04102
        • Maine Health
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Boston Children's Hospital
    • Minnesota
      • Mankato, Minnesota, Estados Unidos, 56001
        • Mankato Clinic/ Javara Research Ltd
    • Nebraska
      • Boys Town, Nebraska, Estados Unidos, 68010
        • Boys Town National Research Hospital
    • New Jersey
      • Irvington, New Jersey, Estados Unidos, 07111
        • Med Clinical Research Partners, LLC
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87131
        • University of New Mexico Health Sciences Center
    • New York
      • Brooklyn, New York, Estados Unidos, 11203
        • SUNY Downstate Medical Center
      • Rochester, New York, Estados Unidos, 14642
        • University of Rochester
      • The Bronx, New York, Estados Unidos, 10467
        • Advantage Clinical Trials
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28203
        • Atrium Health
      • Durham, North Carolina, Estados Unidos, 27705
        • Duke University School of Medicine
      • Wilmington, North Carolina, Estados Unidos, 28401
        • Wilmington Health
    • Pennsylvania
      • Scottdale, Pennsylvania, Estados Unidos, 15683
        • Frontier Clinical Research, LLC
      • Smithfield, Pennsylvania, Estados Unidos, 15478
        • Frontier Clinical Research, LLC
    • South Carolina
      • Greenville, South Carolina, Estados Unidos, 29615
        • Prisma Health Children's Hospital
    • Texas
      • Abilene, Texas, Estados Unidos, 79606
        • Advance Clinical Trial PLLC
      • El Paso, Texas, Estados Unidos, 79902
        • Maspons Pediatric Gastro
      • El Paso, Texas, Estados Unidos, 79902
        • Proactive El Paso, LLC
      • Harlingen, Texas, Estados Unidos, 78550
        • Texas Digestive Specialists
      • Plano, Texas, Estados Unidos, 75093
        • AIM Trials, LLC
      • San Antonio, Texas, Estados Unidos, 78215
        • Sun Research Institute
      • Sugar Land, Texas, Estados Unidos, 77479
        • Pioneer Research Solutions Inc
      • Waxahachie, Texas, Estados Unidos, 75165
        • ClinPoint Trials
    • West Virginia
      • Huntington, West Virginia, Estados Unidos, 25701
        • University Physicians and Surgeons, Inc.
      • Kingwood, West Virginia, Estados Unidos, 26537
        • Frontier Clinical Research

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • ≥12 and <18 years old
  • Patient weighs ≥18 kg at the time the patient provides written assent
  • Females of child-bearing potential must have negative pregnancy test at Visit 1 (serum) and Visit 2 (urine) and confirm the use of appropriate contraception (including abstinence).
  • Patient meets the Rome IV criteria for child/adolescent diagnosis of IBS-C
  • Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
  • Patient meets the entry criteria assessed during the 2-week Screening period.
  • Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
  • Patient must provide written assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures

Exclusion Criteria:

  • Functional diarrhea as defined by Rome IV child/adolescent criteria

  • IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV child/adolescent criteria

  • History of non-retentive fecal incontinence.

  • Required manual disimpaction any time prior to randomization (after consent);

  • Has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process

  • Patient has any of the following conditions:

    • Celiac disease, or positive serological test for celiac disease
    • Cystic fibrosis
    • Hypothyroidism that is untreated or treated with thyroid hormone
    • Down's syndrome or any other chromosomal disorder
    • Active anal fissure
    • Anatomic malformations (eg, imperforate anus)
    • Intestinal nerve or muscle disorders (eg, Hirschprung disease)
    • Neuropathic conditions (eg, spinal cord abnormalities)
    • Lead toxicity, hypercalcemia
    • Neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary (Electronic handheld device)
    • Inflammatory bowel disease
    • Childhood functional abdominal pain syndrome
    • Childhood functional abdominal pain;
    • Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
    • Lactose intolerance that is associated with abdominal pain or discomfort
    • History of cancer other than treated basal cell carcinoma of the skin; (Note: Patients with a history of cancer are allowed provided that the malignancy has been in a complete remission for at least 5 years before the Randomization Visit.)
    • History of diabetic neuropathy.
  • Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.

  • Patient has had surgery that meets any of the following criteria:

    • Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit;
    • Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
    • An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
    • Other major surgery during the 30 days before the Screening Visit
  • History of alcohol or substance abuse

  • Participation in other clinical trials within 1 month prior to Screening

  • Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial

  • If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tenpanor 50 mg BID

Patients will be randomized to receive 50 mg tenapanor twice daily

Participants will receive tenapanor 50 mg BID (total of 100 mg daily)

Experimental: Tenpanor 25 mg BID

Patients will be randomized to receive 25 mg tenapanor twice daily

Participants will receive tenapanor 25 mg BID (total of 50 mg daily)

Comparador de placebos: Placebo Comparator

Patients will be randomized to receive matching placebo twice daily

Participants will be randomized to receive matching placebo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
6/12-week APS (abdominal pain and SBM) +2 response
Periodo de tiempo: 12 weeks

6/12-week APS (abdominal pain and SBM (spontaneous bowel movement)) +2 response, defined as achieving the weekly APS +2 response criteria (i.e., achieving both weekly SBM +2 response and weekly abdominal pain response during the same week) for ≥6 out of the 12 weeks of the RTP.

  • The weekly SBM +2 response is defined as having an increase of ≥2 from baseline in the average weekly SBM frequency for a given week
  • The weekly abdominal pain response is defined as having ≥30% reduction from baseline in the average weekly abdominal pain score for a given week
12 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
6/12-week SBM +2 response
Periodo de tiempo: 12 weeks

6/12-week SBM +2 response: defined as achieving the weekly SBM +2 response for ≥6 out of the 12 weeks of the RTP

12 weeks
6/12-week abdominal pain response
Periodo de tiempo: 12 weeks

6/12-week abdominal pain response: defined as achieving the weekly abdominal pain response for ≥6 out of the 12 weeks of the RTP

12 weeks
Change from baseline in average weekly SBM frequency
Periodo de tiempo: 12 weeks

Change from baseline in average weekly SBM frequency

12 weeks
Change from baseline in average weekly stool consistency score
Periodo de tiempo: 12 weeks

Change from baseline in average weekly stool consistency score

12 weeks
Change from baseline in average weekly abdominal pain score
Periodo de tiempo: 12 weeks

Change from baseline in average weekly abdominal pain score

12 weeks
Overall use of rescue medication
Periodo de tiempo: 12 weeks

Overall use of rescue medication

12 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Jocelyn Tabora, Ardelyx

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de noviembre de 2022

Finalización primaria (Actual)

20 de agosto de 2026

Finalización del estudio (Actual)

20 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

30 de noviembre de 2022

Primero enviado que cumplió con los criterios de control de calidad

30 de noviembre de 2022

Publicado por primera vez (Actual)

8 de diciembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • TEN-01-304

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir